Bioniz Therapeutics Secures $13,000,000 Series A Round

  • Feed Type
  • Date
    8/3/2016
  • Company Name
    Bioniz Therapeutics
  • Mailing Address
    5 Mason St. Irvine, CA 92618 USA
  • Company Description
    Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases that have an immune component.
  • Website
    http://www.bioniz.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $13,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The Series A funding will allow Bioniz to further advance its peptide platform technology focused on selective blockade of key cytokines that modulate serious diseases.
  • M&A Terms
  • Venture Investor
    Takeda Ventures
  • Venture Investor
    Cota Capital
  • Venture Investor
    Investor
  • Venture Investor
    Investor

Trending on Xconomy